Immeuble Vivaldi
11-13 rue René Jacques
Issy-les-Moulineaux 92130
France
33 1 41 09 22 30
https://www.pharnext.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 28
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Daniel E. Cohen | Director | 319,3k | S.O. | 1953 |
Mr. Hugo Brugiere M.Sc. | CEO & Chairman | S.O. | S.O. | S.O. |
Mr. Ilya Chumakov Ph.D., D-Sc | Co-Founder, Chairman of Scientific Advisory Board and Director | S.O. | S.O. | S.O. |
Dr. Rob Quinn Ph.D. | Chief Financial Officer | S.O. | S.O. | 1983 |
Mr. Xavier Paoli M.Sc. | Chief Operating Officer | S.O. | S.O. | S.O. |
Mr. Antoine Gravelle | Gen. Counsel | S.O. | S.O. | S.O. |
Ms. Susanne Dorn | Chief Regulatory Officer | S.O. | S.O. | S.O. |
Mr. Rodolphe Hajj | Chief Pharmacology Officer | S.O. | S.O. | S.O. |
Ms. Viviane Bertrand | Chief Preclinical Drug Devel. Officer | S.O. | S.O. | S.O. |
Mr. Philippe Rinaudo | Chief Data Science Officer | S.O. | S.O. | S.O. |
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
L’ISS Governance QualityScore de Pharnext SA en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..